Influenza Diagnostics Market

Influenza Diagnostics Market Latest Trends

The Influenza Diagnostics Market is moving toward multiplex respiratory testing that can differentiate influenza from several respiratory diseases through a single specimen. Hospitals increasingly prefer respiratory panels when the patient's symptoms do not clearly indicate one pathogen. This approach can simplify clinical workflows because separate sample collections are reduced and physicians can receive a broader diagnostic picture from one testing process.

Point-of-care molecular testing is another important trend. Compact analyzers are bringing nucleic-acid testing into emergency departments, urgent-care centers, outpatient clinics, and physician practices. Automated cartridge systems perform extraction, amplification, detection, and result interpretation with limited operator intervention, allowing facilities without large molecular laboratories to use advanced testing technologies.

Diagnostic manufacturers are also focusing on flexible respiratory panels. Newer platforms allow laboratories to select clinically appropriate targets without purchasing results that are not required for every patient. This model is especially relevant when influenza, respiratory syncytial virus, and other respiratory infections circulate during the same seasonal period.

Home and decentralized testing are influencing product design as well. Developers are simplifying specimen collection, visual interpretation, digital connectivity, and quality controls for users outside conventional laboratories. Combination respiratory tests are becoming increasingly important for this setting because consumers often cannot distinguish respiratory infections by symptoms alone.

Rapid antigen formats continue to retain meaningful adoption because they offer simple workflows and low equipment requirements. Rapid antigen tests accounted for 46.49% of the point-of-care influenza diagnostic test-type segment in a recent assessment, demonstrating that molecular innovation is expanding alongside established rapid testing rather than completely replacing it.

Influenza Diagnostics Market Dynamics

Influenza diagnostics demand is influenced by seasonal disease activity, clinical testing protocols, technology performance, laboratory capacity, diagnostic reimbursement, and access to point-of-care systems. Hospitals generally prioritize sensitive molecular testing for patients whose clinical management depends on reliable confirmation, while outpatient facilities may favor rapid technologies that support same-visit decisions. Public-health laboratories require testing for surveillance, strain monitoring, and outbreak investigation. Manufacturers therefore compete across multiple technology levels rather than relying on one universal diagnostic format. Instrument placement also affects long-term competition because installed molecular analyzers generate recurring demand for proprietary cartridges and reagents. Influenza diagnostics increasingly operate within broader respiratory testing strategies as laboratories seek workflows that can identify several pathogens without maintaining separate testing processes. North America held 37.25% of a recent global influenza diagnostics assessment, illustrating how mature laboratory infrastructure and broad testing access influence market concentration.

Drivers of Market Growth

Increasing demand for rapid and accurate differentiation of respiratory infections.

Influenza, respiratory syncytial virus, coronavirus infections, and other respiratory diseases can produce similar symptoms, making laboratory confirmation increasingly important when clinical decisions depend on pathogen identification. Molecular tests help clinicians differentiate influenza A and B while reducing uncertainty caused by symptom overlap. This capability is particularly important in emergency care, pediatric medicine, elderly populations, and patients with chronic health conditions.

Hospital systems are integrating influenza diagnostics into respiratory-management pathways because an accurate result can influence antiviral use, infection-control measures, patient placement, and additional testing decisions. Emergency departments also benefit from tests that can produce actionable results while the patient remains under evaluation.

Point-of-care systems strengthen this driver by moving diagnostic capability closer to the patient. Automated instruments minimize manual preparation and reduce dependence on specialized molecular staff. Selected rapid molecular influenza assays can deliver results within 15 minutes, supporting treatment and isolation decisions during the initial clinical encounter.

Market Restraints

Differences in diagnostic sensitivity between rapid antigen and molecular testing technologies.

Performance variability remains an important restraint in the Influenza Diagnostics Market. Rapid antigen tests are convenient and easy to operate, but their sensitivity can be lower than molecular assays, particularly when viral concentrations are limited. Negative antigen results may therefore require additional molecular confirmation when influenza is strongly suspected.

Specimen collection can also affect diagnostic reliability. Poor swabbing technique, unsuitable specimen types, delayed collection, improper transportation, and storage conditions can reduce the amount of detectable viral material. These factors can create inconsistent results even when the underlying diagnostic platform performs according to specifications.

Healthcare providers must balance testing speed, accuracy, equipment requirements, and operational cost. Molecular platforms generally offer stronger analytical performance, but they require instrumentation, quality management, and consumable inventory. Traditional RIDT sensitivity can begin at 50% under documented clinical performance ranges, explaining why healthcare organizations may maintain several testing pathways instead of relying on a single assay format.

Market Opportunities

Expansion of multiplex molecular and decentralized point-of-care testing.

Multiplex respiratory diagnostics create a substantial opportunity because clinicians frequently need to determine whether respiratory symptoms are caused by influenza or another infectious agent. Integrated panels can reduce sequential testing and allow laboratories to generate several clinically relevant results from the same respiratory specimen. This creates opportunities for manufacturers offering flexible cartridge menus and scalable testing systems.

Decentralized molecular diagnostics provide another pathway for market development. Smaller automated systems can extend nucleic-acid testing into urgent-care centers, community hospitals, outpatient facilities, and physician practices where conventional PCR laboratories are unavailable. Manufacturers that simplify operation while preserving molecular performance can address a wider customer base.

Connected diagnostic platforms can further strengthen adoption. Automated result transfer, instrument monitoring, quality-control management, and integration with electronic health records provide operational advantages to healthcare organizations managing multiple testing sites.

Rapid influenza diagnostic tests captured 41.1% of test-type demand in a recent global assessment, demonstrating that large existing testing volumes provide manufacturers with an established pathway for upgrading users toward digital or molecular point-of-care systems.

Market Challenges

Maintaining reliable assay performance as influenza viruses continue to evolve.

Influenza viruses undergo genetic change, creating an ongoing requirement for diagnostic developers to monitor primer, probe, and antibody targets against circulating strains. Molecular assays must continue detecting relevant influenza lineages even when mutations occur in viral genomes. Manufacturers therefore maintain sequence-surveillance and assay-verification programs throughout the commercial life of a test.

Multiplexing adds additional technical complexity. Every new target incorporated into a respiratory panel must coexist with other amplification reactions, controls, fluorescent signals, and interpretation algorithms without creating unacceptable interference. This requires extensive analytical and clinical validation.

Seasonal demand patterns add a separate operational challenge. Manufacturers must maintain adequate inventories of swabs, cartridges, reagents, controls, packaging materials, and instrument components even when order volumes change rapidly during respiratory outbreaks. Laboratories also need contingency arrangements when demand temporarily exceeds installed analyzer capacity.

Modern molecular influenza assays demonstrate specificity levels that can reach 95%, placing significant performance expectations on developers as new products enter regulated healthcare markets.

Influenza Diagnostics SWOT Analysis

Strengths

• Influenza diagnostics serve an established clinical requirement because influenza symptoms overlap with multiple respiratory diseases.

• Molecular platforms provide strong analytical performance and support direct identification of influenza viral nucleic acids.

• Rapid tests can be used in decentralized healthcare environments with limited laboratory infrastructure.

• Influenza testing integrates naturally into broader respiratory panels used in hospitals and emergency departments.

• Established manufacturers maintain global distribution, technical service, and regulatory capabilities.

• North America retains a 37.25% market share, reflecting strong installed testing capacity and established clinical adoption.

Weaknesses

• Antigen-based assays can produce negative results when viral concentrations are below their detection thresholds.

• Influenza testing demand varies substantially according to seasonal respiratory-virus circulation.

• Molecular platforms require instruments, trained operators, technical support, and continuous reagent availability.

• Sample quality can influence performance regardless of assay design.

• Viral culture requires specialized facilities and is unsuitable for many immediate treatment decisions.

• The market remains dependent on timely procurement because respiratory seasons can create concentrated purchasing periods, with hospitals accounting for 39% of one current end-user assessment.

Opportunities

• Multiplex respiratory panels allow influenza tests to be packaged with additional viral targets.

• Point-of-care molecular systems can extend high-sensitivity testing into decentralized medical environments.

• Digital connectivity can integrate diagnostic results with clinical records and surveillance systems.

• Simplified test designs create opportunities in pharmacies, community clinics, and home-accessible testing.

• Emerging healthcare systems are expanding molecular diagnostic capacity.

• Asia-Pacific holds close to 23.4% of influenza diagnostic kit demand in one current assessment, supporting additional platform placements across expanding hospital networks.

Threats

• Competitive respiratory panels can reduce demand for standalone influenza tests.

• Regulatory requirements increase clinical-validation and post-market monitoring responsibilities.

• New viral mutations may affect assay target performance.

• Procurement consolidation can increase price pressure on established test suppliers.

• Supply disruptions can affect cartridges, collection materials, enzymes, and laboratory consumables.

• The leading suppliers collectively hold close to 60% of the global market in current competitive assessments, creating significant barriers for smaller entrants seeking broad commercial penetration.

Influenza Diagnostics Segmentation Analysis

The Influenza Diagnostics Market is segmented by product, test type, and end user because these classifications reflect distinct purchasing and clinical-use patterns. Product segmentation separates recurring consumables from instruments, while test-type segmentation distinguishes antigen, culture, immunofluorescence, serological, and molecular approaches. End-user segmentation reflects differences in test volume, clinical urgency, infrastructure, staffing, and required turnaround time. Healthcare organizations may use multiple testing methods within the same institution because emergency departments, outpatient clinics, central laboratories, and research units have different operational requirements. Molecular technologies are increasingly selected when sensitivity and pathogen differentiation are the principal criteria, while rapid antigen technologies remain useful where simplicity and immediate availability are prioritized. Hospitals and clinical laboratories together account for 41.85% market share, confirming the importance of institutional testing environments within the overall segmentation structure.

By Product

Kits and reagents include diagnostic cartridges, test cassettes, extraction materials, amplification reagents, primers, probes, antibodies, buffers, control materials, and other consumables required for patient testing. These products generate repeated demand because each clinical specimen requires a new test-specific consumable. Influenza seasonality can produce concentrated purchasing periods as healthcare organizations increase inventories before anticipated respiratory activity.

Instruments include molecular analyzers, PCR platforms, fluorescence readers, automated extraction systems, immunoassay devices, and syndromic testing equipment. Instrument placement has strategic value because laboratories generally purchase compatible proprietary consumables after installing a platform.

Manufacturers often compete by expanding assay menus available on existing instruments. A respiratory analyzer capable of supporting influenza and additional infectious-disease tests can achieve higher utilization throughout the year.

Kits and reagents represent the leading product category, holding an estimated 65% market share in current market assessments. Their position reflects recurring consumption, broad compatibility with decentralized testing, and continuous replenishment requirements across hospitals and diagnostic laboratories.

By Test Type

Traditional diagnostic tests include rapid influenza diagnostic tests, direct fluorescent antibody tests, viral culture, and serological assays. RIDTs remain widely used because they require limited equipment and provide fast results. Direct fluorescent antibody testing requires suitable microscopy capabilities, while viral culture is used primarily in specialized laboratories and epidemiological applications.

Molecular diagnostic tests include RT-PCR, isothermal amplification, and syndromic multiplex PCR panels. RT-PCR offers strong analytical sensitivity and is widely used in hospital and reference-laboratory environments. Isothermal systems simplify amplification by avoiding conventional thermal cycling, supporting compact instrument designs.

Syndromic multiplex PCR panels identify influenza alongside other respiratory pathogens. These platforms are useful when symptoms cannot reliably identify the infectious agent and clinicians require broader differential diagnosis.

Rapid influenza diagnostic tests hold 41.1% market share within current test-type analysis. Molecular testing continues gaining importance in high-acuity care because improved sensitivity and respiratory multiplexing support more comprehensive diagnostic decision-making.

By End User

Hospitals and clinics use influenza tests in emergency departments, pediatric units, outpatient centers, inpatient wards, and infection-control programs. Their diagnostic strategies often combine rapid point-of-care testing with centralized molecular confirmation when higher sensitivity is required.

Clinical and diagnostic laboratories process respiratory specimens using automated PCR systems, high-throughput analyzers, and multiplex platforms. Purchasing decisions in these facilities depend on sample capacity, assay performance, instrument connectivity, staff requirements, and compatibility with laboratory information systems.

Point-of-care settings prioritize short turnaround times and simple workflows. Urgent-care centers and physician practices can use rapid antigen or automated molecular platforms to obtain results during the patient's visit.

Research and academic institutes use influenza diagnostics for surveillance, viral characterization, assay development, and epidemiological studies. Hospitals and clinics hold a leading 39% market share among current end-user categories because they manage large patient volumes and routinely use influenza testing for treatment and infection-control decisions.

Regional Analysis

Regional performance in the Influenza Diagnostics Market varies according to healthcare infrastructure, public-health surveillance, diagnostic reimbursement, population access, testing capacity, and laboratory modernization. North America maintains the largest installed base of point-of-care and molecular influenza technologies. Europe combines national surveillance systems with extensive hospital and private laboratory networks. Asia-Pacific includes established diagnostic markets and rapidly developing healthcare systems expanding access to molecular testing. Middle East & Africa remains heterogeneous, with advanced diagnostic infrastructure concentrated in large urban centers and Gulf healthcare systems while several African markets continue expanding basic respiratory-testing access. Regional competition is also influenced by procurement models, local manufacturing, regulatory requirements, and availability of trained laboratory personnel. North America represents 40.4% of global influenza diagnostic kit demand in one current assessment, reflecting the region's large hospital network and widespread adoption of decentralized testing.

• North America

North America is the largest regional market for influenza diagnostics, supported by advanced clinical laboratories, extensive outpatient testing networks, structured surveillance systems, and broad access to molecular technologies. The United States represents the principal regional demand center, while Canada maintains established national influenza-monitoring and laboratory-confirmation programs.

Hospitals use influenza diagnostics for emergency triage, inpatient management, infection prevention, and antiviral treatment decisions. Molecular testing is particularly important for hospitalized patients because clinicians require reliable differentiation between respiratory pathogens with overlapping symptoms.

The region also has extensive point-of-care infrastructure. Physician offices, urgent-care centers, retail health settings, community clinics, and emergency departments use rapid tests to shorten the interval between patient presentation and diagnostic decision-making. CLIA-waived molecular systems have extended high-sensitivity testing beyond conventional high-complexity laboratories.

Major manufacturers maintain significant commercial operations in the United States. Abbott, BD, Cepheid, QuidelOrtho, Hologic, Thermo Fisher Scientific, and several international suppliers compete across rapid antigen, molecular, high-throughput, and syndromic testing technologies.

Healthcare organizations increasingly evaluate respiratory platforms based on connectivity and menu flexibility. Systems capable of supporting influenza together with other respiratory pathogens can provide greater utilization than influenza-only technologies.

North America holds 37.25% market share in a recent global influenza diagnostics assessment. The region's leadership reflects established reimbursement pathways, strong hospital procurement, extensive laboratory automation, and broad availability of both molecular and antigen testing.

• Europe

Europe represents a major influenza diagnostics region with established public-health institutions, hospital laboratories, national surveillance programs, and independent diagnostic networks. Germany, the United Kingdom, France, Italy, Spain, Switzerland, and Nordic markets maintain substantial molecular testing capabilities for respiratory infections.

European laboratories increasingly use automated PCR systems and multiplex respiratory panels when accurate differentiation is required. Emergency departments and inpatient facilities benefit from broad respiratory testing because multiple viral infections circulate during common seasonal periods.

The region also contains several major diagnostics manufacturers. Roche, bioMérieux, DiaSorin, QIAGEN, and Siemens Healthineers have strong European laboratory relationships and extensive product portfolios. Their regional presence supports local technical service, instrument installation, reagent distribution, and clinical collaboration.

Regulatory requirements are reshaping product strategies. Diagnostic manufacturers operating under the European regulatory framework must maintain detailed technical documentation, demonstrate clinical performance, and fulfill post-market surveillance obligations. These requirements can favor companies with established regulatory teams and robust quality-management systems.

Hospital laboratories are simultaneously consolidating assay menus. Platforms that support influenza, respiratory syndromic testing, and other infectious-disease applications can reduce the number of independent instruments required within a laboratory.

Europe accounts for 26.5% market share of current influenza diagnostic kit demand. Mature healthcare infrastructure, routine respiratory surveillance, and sustained utilization of molecular testing support the region's position as the second major market after North America.

• Asia-Pacific

Asia-Pacific combines highly developed diagnostic systems with emerging healthcare markets that are expanding access to respiratory testing. Japan, South Korea, Australia, Singapore, and major Chinese metropolitan areas operate sophisticated molecular laboratories. India, Southeast Asia, and other developing markets are adding automated systems across private hospitals and independent laboratory chains.

Large patient populations create significant test-volume requirements. Hospitals need scalable workflows capable of processing respiratory samples during seasonal outbreaks while maintaining turnaround times suitable for clinical decision-making. Rapid antigen technologies remain relevant in facilities where molecular instrumentation is limited.

Local manufacturing is another important characteristic. Asian diagnostics companies produce antigen assays, PCR reagents, sample-collection products, and molecular instruments, creating price competition with multinational suppliers. Domestic manufacturing can also improve supply availability during periods of elevated demand.

Public-health surveillance supports regional testing requirements because Asia-Pacific experiences both seasonal influenza activity and surveillance needs associated with animal-origin influenza viruses. Reference laboratories therefore require technologies suitable for confirmation, characterization, and epidemiological investigation.

Private healthcare investment is accelerating laboratory modernization. Hospital groups increasingly adopt automated respiratory platforms as part of wider infectious-disease testing strategies.

Asia-Pacific represents 23.4% market share of current influenza diagnostic kit demand. Continued expansion of hospital networks, molecular laboratories, and decentralized testing supports further penetration across both developed and emerging healthcare systems.

• Middle East & Africa

The Middle East & Africa influenza diagnostics market contains substantial variation in healthcare infrastructure. Gulf countries operate modern tertiary hospitals with automated molecular analyzers and structured infectious-disease testing programs, while several African healthcare systems rely heavily on centralized reference laboratories and rapid diagnostic technologies.

Saudi Arabia, the UAE, Qatar, and other Gulf markets invest in laboratory automation, electronic medical systems, infection-control programs, and molecular respiratory testing. Large healthcare facilities increasingly use multiplex platforms to distinguish influenza from respiratory infections with similar symptoms.

African markets face different operational conditions. Urban hospitals and national reference laboratories can support PCR testing, while decentralized facilities may prioritize diagnostic technologies that require less equipment, simplified specimen handling, and limited maintenance.

Point-of-care systems offer important development potential in these environments. Closed-cartridge platforms can reduce manual processing requirements and expand access to molecular diagnostics where specialized personnel are limited. Rapid antigen tests also remain important because they can operate without major laboratory infrastructure.

Public-health surveillance and laboratory-strengthening programs continue to improve respiratory diagnostic capacity. Procurement strategies increasingly include equipment training, maintenance agreements, and reagent supply commitments rather than purchasing instruments alone.

Middle East & Africa accounts for 3.9% market share of current influenza diagnostic kit demand. Urban hospital investment and stronger infectious-disease surveillance provide opportunities for gradual expansion despite uneven diagnostic access across the region.

Competitive Landscape

Competition in the Influenza Diagnostics Market is centered on assay sensitivity, turnaround time, instrument footprint, respiratory-panel breadth, regulatory clearance, distribution capabilities, and the size of manufacturers' installed analyzer bases. Major companies include Roche, Abbott, BD, QuidelOrtho, Hologic, bioMérieux, DiaSorin, QIAGEN, Cepheid, Thermo Fisher Scientific, and SEKISUI Diagnostics.

Molecular diagnostics are increasingly important in competitive positioning. Suppliers with automated PCR systems can compete for hospital and reference-laboratory contracts where high sensitivity and workflow integration are critical. Point-of-care manufacturers focus on rapid sample-to-answer systems requiring limited manual preparation.

Respiratory menu breadth has become a significant differentiator. Laboratories increasingly prefer instruments that can identify influenza and additional respiratory pathogens rather than maintaining multiple standalone systems. This creates competitive advantages for manufacturers offering both focused and syndromic panel configurations.

Installed-base strategies also shape market relationships. Replacing a diagnostic platform can require new instrument validation, staff training, middleware configuration, and purchasing changes. Suppliers therefore benefit from customer retention after successful analyzer placement.

Rapid antigen competition remains relevant, particularly in outpatient care and decentralized testing. Digital readers and combination antigen tests are helping manufacturers modernize established rapid-testing formats.

The five leading companies collectively control 55–60% market share in recent competitive assessments. This concentration gives established suppliers strong purchasing relationships while leaving opportunities for specialized companies focused on molecular point-of-care systems, novel amplification technologies, and flexible respiratory panels.

List of Top Influenza Diagnostics Companies

• Abbott Laboratories (U.S.)

• F. Hoffmann-La Roche Ltd. (Switzerland)

• Becton, Dickinson and Company (U.S.)

• Thermo Fisher Scientific Inc. (U.S.)

• QuidelOrtho Corporation (U.S.)

• Hologic, Inc. (U.S.)

• bioMérieux SA (France)

• DiaSorin S.p.A. (Italy)

• Siemens Healthineers AG (Germany)

• QIAGEN N.V. (Netherlands)

• Danaher Corporation/Cepheid (U.S.)

• SEKISUI Diagnostics (U.S.)

• Bio-Rad Laboratories, Inc. (U.S.)

• Seegene Inc. (South Korea)

• Meridian Bioscience, Inc. (U.S.)

Leading Companies by Market Share

• F. Hoffmann-La Roche Ltd. — 21% market share. Roche maintains a leading competitive position through cobas laboratory platforms, Liat point-of-care molecular systems, broad respiratory testing capabilities, international distribution, and an established installed base across hospital and reference laboratories.

• Becton, Dickinson and Company — 17% market share. BD maintains a major presence through rapid influenza testing, automated molecular diagnostics, hospital customer relationships, laboratory instrumentation, and established distribution across institutional and decentralized diagnostic channels.

Investment Trends & Opportunities

Investment in the Influenza Diagnostics Market is increasingly directed toward molecular point-of-care systems, respiratory multiplex platforms, automated laboratory workflows, and scalable manufacturing of diagnostic consumables. Investors favor technologies that can support multiple respiratory targets because broader assay menus increase instrument utilization beyond the peak influenza-testing period.

Platform-based business models remain attractive for established diagnostic manufacturers. Once a molecular analyzer is installed, laboratories frequently purchase proprietary cartridges, reagents, controls, and service agreements. Manufacturers therefore invest in expanding assay menus rather than developing isolated tests without an instrument ecosystem.

Laboratory automation is another major investment area. High-volume healthcare systems require systems capable of handling seasonal increases in respiratory testing without proportional increases in manual staffing. Random-access processing, automated result interpretation, electronic connectivity, and remote instrument management can improve operational efficiency.

Emerging healthcare markets provide additional opportunities for laboratory infrastructure investment. Hospital chains in Asia-Pacific and the Middle East are installing molecular analyzers as part of broader modernization programs. Compact cartridge-based systems are particularly suitable where conventional molecular laboratory resources remain limited.

Strategic acquisitions are also shaping investment priorities. Established diagnostic companies are acquiring technologies that strengthen point-of-care capabilities, assay menus, and decentralized testing. Roche agreed to acquire selected LumiraDx point-of-care technology assets for US$295 million, demonstrating the strategic value placed on platforms capable of bringing sophisticated testing closer to patients.

Product Innovation & Development

Product development in the Influenza Diagnostics Market is focused on faster molecular testing, multiplex pathogen detection, reduced hands-on processing, compact analyzers, flexible respiratory panels, and easier result interpretation. Diagnostic developers are designing systems that deliver molecular-level detection while retaining workflows suitable for point-of-care environments.

Closed-cartridge designs represent a major innovation pathway. These systems combine sample preparation, nucleic-acid extraction, amplification, detection, and software interpretation within one disposable cartridge. This can reduce contamination risk and simplify operator training compared with conventional multi-step molecular workflows.

Respiratory multiplexing is becoming increasingly flexible. Broad syndromic panels are useful for complex hospital patients, while smaller panels can target the respiratory viruses most relevant to routine clinical decisions. Flexible platforms allow laboratories to align testing depth with patient condition and institutional protocols.

Digital technologies are also changing antigen diagnostics. Instrument-based interpretation can reduce subjectivity associated with manually reading visual test lines. Electronic connectivity allows results to transfer directly into clinical systems and supports centralized oversight of decentralized testing locations.

Manufacturers are also improving point-of-care testing speed. Rapid molecular platforms increasingly aim to provide clinically useful answers during the patient encounter without sacrificing the analytical benefits associated with nucleic-acid detection. Selected FDA-cleared molecular assays can produce influenza results in under 15 minutes, demonstrating the convergence of rapid-testing convenience and advanced molecular technology.

Recent Developments (2023–2026)

• In March 2026, Baebies received U.S. regulatory authorization for the FINDER Flu A&B/SARS-CoV-2 molecular test, expanding decentralized RT-PCR testing for influenza and coronavirus differentiation.

• In February 2026, LEX Diagnostics received U.S. clearance for its VELO Respiratory Test, strengthening the availability of automated multiplex molecular testing for influenza and other respiratory infections.

• In December 2025, DiaSorin obtained U.S. authorization for the LIAISON NES FLU A/B, RSV & COVID-19 assay, expanding its near-patient molecular respiratory-testing portfolio.

• In August 2025, QIAGEN secured U.S. clearance for updated QIAstat-Dx respiratory panel configurations designed to provide flexible molecular testing for influenza and additional respiratory pathogens.

• In July 2025, Roche received U.S. clearance for the cobas Respiratory 4-flex assay, introducing a flexible high-throughput molecular approach for differentiating major respiratory viruses.

• In April 2025, Roche obtained U.S. clearance for updated cobas Liat respiratory molecular assays, strengthening rapid influenza testing capabilities in decentralized clinical environments.

Scope of the Influenza Diagnostics Market Report

The Influenza Diagnostics Market report covers diagnostic technologies used to detect influenza infections across hospitals, clinics, diagnostic laboratories, point-of-care facilities, research organizations, and public-health settings. The scope evaluates product adoption, diagnostic methodology, end-user requirements, geographic performance, competitive positioning, investment activity, and product-development strategies.

Product coverage includes kits and reagents as well as diagnostic instruments. Kits and reagents include cartridges, antigen-test components, molecular reagents, extraction materials, primers, probes, antibodies, controls, and related consumables. Instrument coverage includes molecular analyzers, PCR systems, fluorescence readers, immunoassay devices, and automated respiratory diagnostic platforms.

Test-type coverage includes traditional diagnostic technologies and molecular diagnostic tests. Traditional approaches comprise RIDTs, direct fluorescent antibody testing, viral culture, and serological assays. Molecular technologies include RT-PCR, isothermal amplification, and syndromic multiplex PCR panels.

End-user analysis examines hospitals and clinics, clinical and diagnostic laboratories, point-of-care settings, and research and academic institutes. The report evaluates how testing priorities differ according to throughput, required sensitivity, infrastructure, staffing, and turnaround expectations.

Regional coverage includes North America, Europe, Asia-Pacific, and Middle East & Africa. The competitive scope assesses multinational and specialist suppliers based on technology portfolios, regulatory approvals, platform placement, distribution reach, and respiratory-testing capabilities.

The report uses three primary segmentation dimensions to evaluate market structure while also examining diagnostic innovation, regulatory trends, public-health surveillance, decentralized testing, laboratory automation, strategic investments, and manufacturer developments influencing future influenza diagnostic adoption.